Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039

Theravance Biopharma, Inc.

Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).
Eugia granted royalty-free license to market generic version on or after April 23, 2039.
Settlement subject to review by U.S. DOJ and FTC as required by law.
Patent litigation continues against two other ANDA filers: Cipla and Mankind Pharma.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.